Cart
sales@molnova.com
Beta-Hydroxyisovaleric acid
CAS No. 625-08-1
Beta-Hydroxyisovaleric acid( —— )
Catalog No. M15365 CAS No. 625-08-1
Used as pharmaceutical intermediates.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | 38 | In Stock |
|
| 1G | 52 | In Stock |
|
Biological Information
-
Product NameBeta-Hydroxyisovaleric acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionUsed as pharmaceutical intermediates.
-
DescriptionUsed as pharmaceutical intermediates.
-
In VitroThe reduced activity of methylcrotonyl-CoA carboxylase (MCC) leads to an elevated excretion of 3-methylcrotonic acid, the product of its hydration (3-hydroxyisovaleric acid: 3-HIA), and 3-methylcrotonylglycine, formed by conjugation with glycine.
-
In VivoIn male mice (ICR/Jcl) at 8 weeks of age fed the biotin-deficient diet for 6 weeks, the concentration of urinary 3-Hydroxyisovaleric acid is 114.2 mM creatinine, which is higher than the concentration of 35.2 mM creatinine in mice fed the biotin-deficient diet for 4 weeks.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number625-08-1
-
Formula Weight118.13
-
Molecular FormulaC5H10O3
-
Purity>98% (HPLC)
-
SolubilityLimited solubility
-
SMILESCC(C)(O)CC(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sabourin PJ, Bieber LL. Arch Biochem Biophys. 1981 Jan;206(1):132-44.
molnova catalog
related products
-
Hydroxytyrosol 1-O-g...
Hydroxytyrosol 1-O-glucoside plays a key role in the tolerance of X. fastidiosa to cv. Hydroxytyrosol 1-O-glucoside has antioxidant activity.
-
BT173
BT173 is a novel inhibitor of homeodomain interacting protein kinase 2 (HIPK2 ), attenuating renal fibrosis through suppression of the TGF-?1/Smad3 pathway.
-
GT 949
GT 949 is a selective excitatory positive allosteric modulator of amino acid transporter-2 (EAAT2) (EC50: 0.26 nM).
